Two Novel Human Anti-ErbB2 Immunoagents Are Active on Trastuzumab-Resistant Tumours

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6605499
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Effects of a Second-Generation Human Anti-ErbB2 ImmunoRNase on Trastuzumab-Resistant Tumors and Cardiac Cells

Protein Engineering, Design and Selection
BiochemistryBioengineeringMolecular BiologyBiotechnology
2014English

Enzastaurin Inhibits Tumours Sensitive and Resistant to Anti-Egfr Drugs

British Journal of Cancer
Cancer ResearchOncology
2008English

Nectin-4 Cis-Interacts With ErbB2 and Its Trastuzumab-Resistant Splice Variants, Enhancing Their Activation and DNA Synthesis

Scientific Reports
Multidisciplinary
2019English

Preexisting Oncogenic Events Impact Trastuzumab Sensitivity in ERBB2-amplified Gastroesophageal Adenocarcinoma

Journal of Clinical Investigation
Medicine
2014English

Anti-Igf-1r Monoclonal Antibody Inhibits the Carcinogenicity Activity of Acquired Trastuzumab-Resistant SKOV3

Journal of Ovarian Research
GynecologyOncologyObstetrics
2014English

Structure Determination of Active Full Length Human Taspase1: Towards Novel Anti-Cancer Therapeutics

Biophysical Journal
Biophysics
2019English

Indoleamides Are Active Against Drug-Resistant Mycobacterium Tuberculosis

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2013English

The Anti-erbB3 Antibody MM-121/SAR256212 in Combination With Trastuzumab Exerts Potent Antitumor Activity Against Trastuzumab-Resistant Breast Cancer Cells

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2013English

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy